clinical trial · NCT07005713
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria
BeiGene·phase1·completed·n = 34
Chronic Spontaneous UrticariaBGB-16673Placebo
brief summary
This study is a Phase 1b, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of multiple-ascending doses of BGB-16673 in adults with chronic spontaneous urticaria (CSU).
started
Jul 19, 2025
primary completion
Apr 16, 2026
completion
Apr 16, 2026
last updated
Jun 18, 2026
official title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple- Ascending Doses of BGB-16673 in Patients With Chronic Spontaneous Urticaria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol